Table 4. Baseline and procedural characteristics of propensity score matched cohort .
| BMS (n = 87) | DES (n = 87) | p value | |
| Age (years) | 72.5 ± 10.8 | 72.1 ± 11.3 | 0.99 |
| Gender (male) | 74 (85.1%) | 76 (87.4%) | 0.83 |
| Diabetes | 38 (43.7%) | 39 (44.8%) | 1.00 |
| Hypertension | 74 (85.1%) | 67 (77.0%) | 0.25 |
| Hypercholesterolemia | 45 (52.1%) | 68 (52.7%) | 1.00 |
| Smoking | 49 (51.7%) | 39 (44.8%) | 0.45 |
| Body mass index (Kg/m2) | 25.3 ± 4.3 | 25.0 ± 3.7 | 0.69 |
| PAOD | 11 (12.6%) | 10 (11.5%) | 1.00 |
| Previous MI | 26 (31.3%) | 26 (31.3%) | 1.00 |
| Old stroke | 15 (17.2%) | 7 (8.0%) | 0.11 |
| Chronic kidney disease | 38 (43.7%) | 34 (39.1%) | 0.64 |
| eGFR | 65.5 ± 29.6 | 66.8 ± 32.3 | 0.78 |
| LVEF (%) | 50.0 ± 12.4 | 51.0 ± 11.5 | 0.57 |
| Clinical presentation | |||
| Stable angina | 46 (52.9%) | 44 (50.6%) | 0.88 |
| Unstable angina | 17 (19.5%) | 15 (17.2%) | 0.85 |
| Non-ST elevation MI | 24 (27.6%) | 28 (32.2%) | 0.62 |
| SYNTAX score (25%-75% range) | 30 (21-39) | 30 (20-39) | 0.98 |
| SYNTAX score > 32 | 37 (42.5%) | 34 (39.1%) | 0.76 |
| EuroSCORE (25%-75% range) | 7 (4-9) | 7 (4-10) | 0.78 |
| EuroSCORE > 6 | 42 (48.3%) | 39 (44.8%) | 0.76 |
| Lesion location, n (%) | |||
| Ostial/shaft | 35 (40.2%) | 32 (36.8%) | 0.76 |
| Bifurcation | 58 (66.7%) | 62 (71.3%) | 0.62 |
| Extent of diseased vessel n (%) | |||
| LM only | 9 (10.3%) | 4 (4.6%) | 0.25 |
| LM plus 1-vessel disease | 17 (19.5%) | 12 (13.8%) | 0.42 |
| LM plus 2-vessel disease | 26 (29.9%) | 31 (35.6%) | 0.52 |
| LM plus 3-vessel disease | 35 (40.2%) | 40 (46.0%) | 0.44 |
| RCA disease n (%) | 42 (48.3%) | 49 (56.3%) | 0.36 |
| Stent length in LM (mm) | 17.3 ± 6.7 | 22.6 ± 7.1 | < 0.01 |
| Stent diameter (mm) | 3.8 ± 0.7 | 3.7 ± 1.4 | 0.55 |
| Bifuncation LM stenting (n = 120) | |||
| Cross-over tech with 1 stent | 46 (79.3%) | 44 (77.2%) | 0.82 |
| Technique with 2 stent | |||
| T-stenting, n (%) | 8 (13.8%) | 7 (11.3%) | 0.79 |
| Crush, n (%) | 0 | 5 (8.1%) | 0.06 |
| Culottes, n (%) | 3 (5.2%) | 5 (8.7%) | 0.72 |
| V stenting , n (%) | 1 (1.7%) | 1 (1.6%) | 1.00 |
| Kissing post-dilation | 35 (40.2%) | 46 (52.9%) | 0.13 |
| Use of glycoprotein IIb-IIIa inhibitors | 13 (14.9%) | 26 (29.9%) | 0.03 |
| Use of IABP | 9 (10.3%) | 11 (12.6%) | 0.81 |
| IVUS guidance | 5 (5.7%) | 26 (29.9%) | < 0.01 |
| Rotablation | 1 (1.1%) | 10 (11.5%) | < 0.01 |
eGFR, estimated glomerular filtration rate; IABP, intraaortic balloon pump; IVUS, intravascular ultrasound; LM, left main coronary artery; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAOD, peripheral arterial obstructive disease; RCA, right coronary artery.